Precision Perinatology of Moringa oleifera Lam. in Pregnancy: Trimester-specific Pharmacokinetics, Placental Transfer Biology, and Clinically Actionable Drug-supplement Interaction Risk – A Systematic Review and Translational Synthesis

Abstract

The clinical use of botanical supplements during pregnancy is often guided more by tradition than by pharmacologic certainty, and Moringa oleifera Lam. is no exception. Despite expanding interest in its antioxidant, metabolic, and nutritional properties, no prior synthesis has systematically integrated trimester-specific maternal physiology, placental transport biology, and clinically relevant drug-supplement interaction risk within a precision perinatology framework. We conducted a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines to examine the pharmacokinetic, mechanistic, placental, and interaction literature relevant to M. oleifera in maternal–fetal medicine. Comprehensive searches of biomedical databases and reference lists identified 1320 records; after duplicate removal and eligibility assessment, 47 studies met predefined inclusion criteria. Risk of bias was appraised using design-appropriate tools. Evidence was grouped into mechanistic domains: maternal absorption–distribution–metabolism–excretion remodeling, placental transporter systems, physiologically based pharmacokinetic (PBPK) modeling, and clinical interaction signals. Across heterogeneous designs, signals emerged for cytochrome P450 3A4 modulation, phase II pathway involvement, absorption interference related to fiber-rich preparations, and measurable pharmacokinetic interaction in nonpregnant adults. Parallel literature documents trimester-dependent shifts in enzyme activity, renal clearance, plasma volume, protein binding, and placental transporter regulation – variables that plausibly alter both maternal exposure and fetal transfer. Direct pregnancy-specific pharmacokinetic data for Moringa are absent, and no study has quantified fetal exposure. We therefore propose a multiscale translational model linking molecular bioactives to maternal absorption, distribution, metabolism, and excretion remodeling, placental flux, and clinically actionable risk stratification. The findings underscore a critical gap between widespread use and mechanistic certainty, and call for trimester-resolved pharmacokinetic, placental perfusion, and PBPK validation studies before routine perinatal integration.